PFE - The Race To Erase COVID-19
The Problem
You are not going to find a standard valuation metric to validate the stock price of any of the leading COVID-19 vaccines that are currently in clinical trials. To the contrary, the measure is market potential if, perchance, one or more of these companies gain regulatory approval. All the leading candidates appear to have sufficient funding from myriad government, private and philanthropic sources. Early-stage clinical trial results are slowly trickling into the public domain, creating outsized market moves to both the upside on trial successes and to the downside on profit-taking.
Historically, the